Roberto Iezzi1, Maurizio Pompili2, Alessandro Posa3, Francesca Carchesio3, Massimo Siciliano4, Brigida Eleonora Annicchiarico4, Salvatore Agnes5, Felice Giuliante6, Matteo Garcovich4, Lucia Cerrito4, Francesca Romana Ponziani4, Michele Basso7, Alessandra Cassano8, Gian Lodovico Rapaccini2, Anna Maria De Gaetano9, Antonio Gasbarrini2, Riccardo Manfredi9. 1. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radiologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Roma, Italy; Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italy. Electronic address: roberto.iezzi@policlinicogemelli.it. 2. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Gastroenterologiche, Endocrino-metaboliche e Nefro-Urologiche, Roma, Italy; Università Cattolica del Sacro Cuore, Istituto di Medicina Interna e Gastroenterologia, Roma, Italy. 3. Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italy. 4. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Gastroenterologiche, Endocrino-metaboliche e Nefro-Urologiche, Roma, Italy. 5. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Chirurgia Generale e del Trapianto di Fegato, Dipartimento di Scienze Gastroenterologiche, Endocrino-metaboliche e Nefro-Urologiche, Roma, Italy; Università Cattolica del Sacro Cuore, Istituto di Chirurgia Generale e del Trapianto di Fegato, Roma, Italy. 6. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Chirurgia Generale ed Epatobiliare, Dipartimento di Scienze Gastroenterologiche, Endocrino-metaboliche e Nefro-Urologiche, Roma, Italy; Università Cattolica del Sacro Cuore, Istituto di Chirurgia Generale ed Epatobiliare, Roma, Italy. 7. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Oncologia Medica, Dipartimento di Scienze Gastroenterologiche, Endocrino-metaboliche e Nefro-Urologiche, Roma, Italy. 8. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Oncologia Medica, Dipartimento di Scienze Gastroenterologiche, Endocrino-metaboliche e Nefro-Urologiche, Roma, Italy; Università Cattolica del Sacro Cuore, Istituto di Oncologia Medica, Roma, Italy. 9. Fondazione Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radiologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Roma, Italy; Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italy.
Abstract
PURPOSE: This study was designed to assess the feasibility and safety of a single-step combined therapy using radiofrequency ablation and transarterial chemoembolization (RFA + TACE) in patients with hepatocellular carcinoma (HCC) and uncontrolled coagulopathy. The study also aimed to compare the effectiveness of this approach with TACE alone, performed in a control group. MATERIAL AND METHODS: One hundred and forty-three consecutive cirrhotic patients having a single HCC < 8 cm were enrolled in this observational prospective single-center study from January 2010 to June 2017 and were divided, according to coagulation tests, into three groups (A: low risk; B: intermediate risk and C: high risk of bleeding). The feasibility and safety of a single-step combined treatment (RFA followed by TACE) were evaluated in terms of technical success rate, periprocedural complications, and laboratory values variations. Tumor response obtained at 1-month CT follow-up for group C was compared with that of control group, composed by 16 matched patients with severe coagulopathy and single HCC < 8 cm, who underwent only TACE in a previous period, performed by the same operator. RESULTS: Technical success was achieved in all patients, without any major complications. Minor complications rate was significantly higher in group C after RFA; however, the patients were successfully treated with subsequent TACE therapy, without any differences between pre- and post-procedural laboratory values. One-month complete response rates were similar in all the three groups; however, the response rates of group C were significantly higher as compared to that of the control TACE Group (p < .001). CONCLUSION: The single-step RFA plus TACE therapy allows expansion of the indication for percutaneous thermal ablation, allowing to also include cases previously contraindicated due to the procedural high-risk of complications associated with bleeding, thus improving short-term patient outcome.
PURPOSE: This study was designed to assess the feasibility and safety of a single-step combined therapy using radiofrequency ablation and transarterial chemoembolization (RFA + TACE) in patients with hepatocellular carcinoma (HCC) and uncontrolled coagulopathy. The study also aimed to compare the effectiveness of this approach with TACE alone, performed in a control group. MATERIAL AND METHODS: One hundred and forty-three consecutive cirrhotic patients having a single HCC < 8 cm were enrolled in this observational prospective single-center study from January 2010 to June 2017 and were divided, according to coagulation tests, into three groups (A: low risk; B: intermediate risk and C: high risk of bleeding). The feasibility and safety of a single-step combined treatment (RFA followed by TACE) were evaluated in terms of technical success rate, periprocedural complications, and laboratory values variations. Tumor response obtained at 1-month CT follow-up for group C was compared with that of control group, composed by 16 matched patients with severe coagulopathy and single HCC < 8 cm, who underwent only TACE in a previous period, performed by the same operator. RESULTS: Technical success was achieved in all patients, without any major complications. Minor complications rate was significantly higher in group C after RFA; however, the patients were successfully treated with subsequent TACE therapy, without any differences between pre- and post-procedural laboratory values. One-month complete response rates were similar in all the three groups; however, the response rates of group C were significantly higher as compared to that of the control TACE Group (p < .001). CONCLUSION: The single-step RFA plus TACE therapy allows expansion of the indication for percutaneous thermal ablation, allowing to also include cases previously contraindicated due to the procedural high-risk of complications associated with bleeding, thus improving short-term patient outcome.